Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD5 | P21918 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7481044 | 0.98 | KDM4E (0.45) | KDM4EMAPTGAAHTTDRD2 | |
| SCHEMBL21526562 | 0.87 | DRD1 (0.46) | KDM4EMAPTGAAHTTDRD2 | |
| SCHEMBL20867781 | 0.84 | KDM4E (0.59) | KDM4EMAPTGAAHTTPKM | |
| SCHEMBL20354517 | 0.81 | RIPK1 (0.51) | MAPTGAAHTTDRD2DRD1 | |
| SCHEMBL14863559 | 0.80 | HTT (0.43) | MAPTHTTDRD2DRD1DRD4 | |
| SCHEMBL7485284 | 0.80 | KDM4E (0.39) | KDM4EMAPTGAAPKMNPC1 | |
| SCHEMBL3353793 | 0.77 | MAPT (0.37) | KDM4EMAPTGAAHTTPKM | |
| SCHEMBL2061673 | 0.77 | REN (0.38) | KDM4EMAPTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL18255843 | 0.76 | PIK3CA (0.43) | HTTDRD2DRD1DRD4DRD5 | |
| SCHEMBL23251650 | 0.76 | PIK3CA (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3604306-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1910321-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004959-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |
| US-6489322-B1 | BENZOXAZEPINES AS SELECTIVE INHIBITORS OF THE NEURONAL ISOFORM OF NITRIC OXIDE SYNTHASE FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ASTRAZENECA AB (SE) | 2002-12-03 | — | — | US | disclosed |
| EP-0983268-B1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | KDM4E 729/4885MAPT 3881/4885GAA 3538/4885 |
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | WEE1, WEE2, PDPK1 | KDM4E 1284/4885MAPT 4388/4885GAA 3892/4885 |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | WEE1, WEE2, PDPK1 | KDM4E 1284/4885MAPT 4388/4885GAA 3892/4885 |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | KDM4E 3840/4885MAPT 87/4885GAA 245/4885 |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | WEE1, WEE2, CCNK | KDM4E 1635/4885MAPT 4695/4885GAA 3833/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | KDM4E 729/4885MAPT 3881/4885GAA 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.